CoChat

Incretin Effects on β-Cell Function, Replication, and Mass

Open access
Garber, Alan J. · 2011 · Diabetes Care

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

There is a progressive deterioration in β-cell function in patients with type 2 diabetes. At diagnosis, islet function may be reduced by up to 50% compared with healthy control subjects, and there is also likely to be a reduction in β-cell mass of up to 60%. The reduction in β-cell mass is due to accelerated apoptosis. Currently, few pharmacological therapies address this reduction in β-cell mass and function. This means that patients are generally subjected to an increasing polypharmacy to control their diabetes, with most eventually being treated by insulin. Incretin hormones, which are released from the gastrointestinal tract after a meal, enhance glucose-dependent insulin secretion from the pancreas, aiding the overall regulation of glucose homeostasis in healthy subjects. In addition, these hormones, especially glucagon-like peptide (GLP)-1, have a number of protective effects on the β-cells, including a reduction in apoptosis and enhancement of β-cell proliferation and neogenesis. These benefits are lost to a significant extent in patients with diabetes. The recently developed diabetes therapies, GLP-1 receptor agonists, such as exenatide and liraglutide, appear to have beneficial effects on β-cell function and hence offer promise for durable glycemic control as well as potentially reducing the micro- and macrovascular complications associated with type 2 diabetes. The clinical course of type 2 diabetes is characterized by a progressive decline in β-cell mass and function. Although the elevated levels of fasting glucose and impairment of insulin action in peripheral tissues may predate the diagnosis of type 2 diabetes, chronic hyperglycemia only results after a prolonged period of β-cell degeneration, a process that may begin as much as 12 years before diagnosis, involving a progressive reduction in functionality and mass (1,2). In the UK Prospective Diabetes Study, it was estimated that, at diagnosis, type 2 diabetic patients may have already lost up …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-s230

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Pharmacological, but not physiological, levels of GLP-1 enhance insulin secretion in patients with type 2 diabetes. Reproduced with permission from Springer, from Højberg et al. (16) (A), and Vilsbøll et al. (17) (B).
Figure 1 Pharmacological, but not physiological, levels of GLP-1 enhance insulin secretion in patients with type 2 diabetes. Reproduced with permission from Springer, from Højberg et al. (16) (A), and Vilsbøll et al. (17) (B).CC BY-NC-ND · PubMed Central
Figure 2 Liraglutide improves HOMA (A) β-cell function and (B) the proinsulin-to-insulin ratio. Data are from Degn et al. (38).
Figure 2 Liraglutide improves HOMA (A) β-cell function and (B) the proinsulin-to-insulin ratio. Data are from Degn et al. (38).CC BY-NC-ND · PubMed Central
Figure 3 Effect of liraglutide (1.2 and 1.8 mg) on HOMA-B function in the (A) LEAD-1 and (B) LEAD-2 trials. Data are from Marre et al. (50) and Nauck et al. (51).
Figure 3 Effect of liraglutide (1.2 and 1.8 mg) on HOMA-B function in the (A) LEAD-1 and (B) LEAD-2 trials. Data are from Marre et al. (50) and Nauck et al. (51).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

See all 93

Metadata

Authors
Garber, A. J.
Affiliations
Baylor College of Medicine (US)
Corresponding author
Garber, Alan J.
Venue
Diabetes Care
Published
2011-04-22
Volume
34
Issue
Supplement_2
Pages
S258-S263
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2159416991
Cited by
92
References
60
Citations by year
2025: 3 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 3 · 2017: 6 · 2016: 10 · 2015: 10 · 2014: 13 · 2013: 8 · 2012: 7
FWCI
9.48
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
incretins, type 2 diabetes, beta-cell function, beta-cell mass, beta-cell apoptosis, beta-cell proliferation, beta-cell neogenesis, glucagon-like peptide-1, GLP-1 receptor agonists, exenatide, liraglutide, glucose-dependent insulin secretion, glucose homeostasis, beta cell degeneration
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Peptides, Venoms, Receptors, Glucagon, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incretin Effects on β-Cell Function, Replication, and Mass. https://app.cochat.ai/papers/10.2337/dc11-s230
The paper
Garber, A. J. (2011). Incretin Effects on β-Cell Function, Replication, and Mass. Diabetes Care. https://doi.org/10.2337/dc11-s230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.